Evopoint announced a strategic partnership with Porton to comprehensively improve R&D and business topology
On August 22, 2022, Suzhou Evopoint
Biosesciences Co., Ltd. (hereinafter referred to as Evopoint) and Porton Pharma
Solutions (stock ticker: 300363, stock abbreviation: Porton) jointly announced
a strategic partnership. The two parties will carry out long-term strategic
cooperation around the integrated customized R&D, production and supply of
innovative drugs. It marks the deepening of the 5-year cooperation between
Evopoint and Porton in the past to a new stage of development, and is also an
important milestone in the friendly win-win cooperation between the two parties.
Mr. Le Meijie, General Manager of Evopoint, Mr. Ju Nianfeng, one of the
cofounder, Chairman and General Manager of Porton, and Mr. Ji Yaohui, Senior
Deputy General Manager and General Manager of Small Molecular Business
Department of Porton, led key team members from both parties to attend the
signing ceremony.
Evopoint and Porton have
officially started business cooperation since 2017, with many cooperation
projects under implementation at present. Since its establishment for 5 years,
Evopoint has devoted itself to constructing optimal targeted treatment
platform, antibiotic platform and PROTAC platform. At present, 6 products in
Evopoint are under clinical development at home and abroad, and 15 products are
undergoing preclinical trials. In April 2022, FDA approved XNW4107 developed by
Evopoint to be involved in the international key Phase III clinical trial
scheme for indications of HAP/VAP. Its core products include BLI inhibitors,
EZH2 inhibitors, hURAT1 inhibitors, PORCN (Wnt) inhibitors, etc. in the fields
of tumors, anti-infection and metabolic diseases primarily. In the aspect of
operation model, Evopoint adopts a global clinical development strategy
combining efficient internal R&D and outsourcing services to accelerate
product launch.
Porton always regards our
Chinese market as its important strategic marketing, actively expands the
market of high-quality customers in China, and supports drug development of
domestic customers with the same standards of serving overseas pharmaceutical
customers for >17 years. At present, Porton has established an
"end-to-end" service platform to support the market demand of
domestic key customers. With the establishment of Minhang (Shanghai) R&D
Center of Porton in the fourth quarter of 2022 and the continuous construction
of new services and capabilities, we look forward to enabling increasingly more
Chinese customers to develop innovative drugs, accelerating the customer lines
into key clinical phases and achieving successful launch of products, so as to
benefit the public with high-quality medicines earlier.
Mr. Meijie Le, CEO of
Evopoint, said that: “The professionalism and engagement of Porton's team have
been proven through the past 5 years of cooperation. Cooperation with Porton
has accelerated the development and commercialization of important innovative
drug lines in Evopoint, and our team is confident in the broad prospects of our
own product lines. We are very pleased to sign this strategic cooperation
agreement with Porton, which points out that Porton will provide Evopoint with
comprehensive CDMO services and support Evopoint in developing and
commercializing differentiated innovative drug products worldwide. The signing
of this agreement is an important milestone, marking that many products in Evopoint
are about to be involved into late-stage clinical trials and
commercialization.”
Mr. Nianfeng Ju, one of the
co-founders, chairman and general manager of Porton, said that: “The strategic
partnership with Evopoint marks a new stage of cooperation in the past 5 years
between the two parties, suggesting mutual trust and recognition between Porton
and Evopoint. Evopoint is committed to providing solutions to unmet clinical
needs worldwide, and several product lines in Evopoint are undergoing clinical
trials. We are looking forward to providing Evopoint with professional,
efficient and reliable CDMO services, accelerating the development and
marketing of their products in both China and the United States, and benefiting
patients as soon as possible.”
About Porton
